insights_auto
Kodėl „GIS“ sumažėjo 2,18%?
Įsigilintichevron_right
GIS:FRA
Gilead Sciences, Inc
151,84 €
arrow_downward
−2,18%(−3,38) 1 D.
11-17, 08:01:02 GMT+1 · EUR
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „GIS“ įžvalgos...
Atidaryti
151,84 €
Aukšta
151,84 €
Žema
151,84 €
Rinkos kapitalizacija
207,86 mlrd.
Vid. kiekis
224,00
Apimtis
0,00
52 sav. aukšta
157,14 €
52 sav. žema
100,42 €
Darbuotojų skaičius
17 tūkst.
Atidaryti
151,84 €
Aukšta
151,84 €
Žema
151,84 €
Rinkos kapitalizacija
207,86 mlrd.
Vid. kiekis
224,00
Apimtis
0,00
52 sav. aukšta
157,14 €
52 sav. žema
100,42 €
Darbuotojų skaičius
17 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Investing.com Canada
·
prieš 1 valandą
Form 144 GILEAD SCIENCES For: 17 November By Investing.com
Seeking Alpha
·
prieš 3 valandas
Gilead: Growth Supports A Hold Despite A Valuation Premium
Yahoo Finance
·
prieš 7 valandas
Gilead Sciences (GILD) Grants Royalty Free Ebola Drug Licenses For Lower Income Countries
Investing.com
·
prieš 10 valandų
Gilead signs licensing deals for Ebola drug obeldesivir
Profilis
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Apie „Gilead Sciences, Inc“
Generalinis direktoriusDaniel O'Day
Darbuotojai17 tūkst.
Įkurta1987-06-22
Pagrindinė būstinėFoster Sitis, Kalifornija, Jungtinės Valstijos
SektoriusHealth Care
Pramonės sritis-
Svetainėgilead.com